Citi Pharma Limited (PSX:CPHL)
Pakistan
· Delayed Price · Currency is PKR 83.56
+0.65 (0.78%)
At close: May 15, 2025
Citi Pharma Cash Flow Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2018 - 2019 |
| Net Income | 830.91 | 833.46 | 657.98 | 653.69 | 351.77 | 143.42 | Upgrade
|
| Depreciation & Amortization | 165.05 | 138.22 | 90.59 | 76.83 | 65.69 | 49.59 | Upgrade
|
| Other Amortization | - | - | - | - | - | 2.69 | Upgrade
|
| Loss (Gain) From Sale of Investments | 20.05 | -29.28 | 35.12 | 4.48 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 4.78 | 4.78 | - | - | - | - | Upgrade
|
| Other Operating Activities | -169.53 | 55.33 | -26.27 | 136.33 | 49.47 | 21.37 | Upgrade
|
| Change in Accounts Receivable | -1,650 | -282.69 | -480.58 | -957.02 | -145.08 | -139.21 | Upgrade
|
| Change in Inventory | -1,446 | -594.39 | -917.35 | -913.44 | 113.53 | -789.68 | Upgrade
|
| Change in Accounts Payable | 1,381 | 1,359 | 260.08 | 782.19 | -188.6 | 849.6 | Upgrade
|
| Change in Other Net Operating Assets | -50.49 | -146.79 | 51.42 | -106.03 | -22.38 | -43.68 | Upgrade
|
| Operating Cash Flow | -913.66 | 1,338 | -329 | -322.97 | 224.4 | 94.09 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | 138.49% | -65.60% | Upgrade
|
| Capital Expenditures | -181.62 | -568.2 | -954.47 | -600.46 | -276.7 | -115.19 | Upgrade
|
| Investment in Securities | 19.82 | 52.83 | 179.77 | -312.12 | - | -82.72 | Upgrade
|
| Other Investing Activities | -8.4 | 3.43 | -6.13 | -8.91 | - | -2.67 | Upgrade
|
| Investing Cash Flow | -170.2 | -511.94 | -780.83 | -921.48 | -276.7 | -200.58 | Upgrade
|
| Short-Term Debt Issued | - | - | 1,246 | 509.37 | 122.8 | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | 300 | 146.95 | 117.81 | Upgrade
|
| Total Debt Issued | 1,517 | - | 1,246 | 809.37 | 269.74 | 117.81 | Upgrade
|
| Short-Term Debt Repaid | - | -331.54 | - | - | -5 | -2.1 | Upgrade
|
| Long-Term Debt Repaid | - | -56.17 | -383.24 | -148.3 | -74.99 | -7.86 | Upgrade
|
| Total Debt Repaid | 72.93 | -387.7 | -383.24 | -148.3 | -79.99 | -9.96 | Upgrade
|
| Net Debt Issued (Repaid) | 1,590 | -387.7 | 863.24 | 661.07 | 189.75 | 107.85 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 2,326 | - | Upgrade
|
| Common Dividends Paid | -742.78 | -571.15 | - | -311.54 | - | - | Upgrade
|
| Other Financing Activities | - | - | - | -521.38 | 521.38 | - | Upgrade
|
| Financing Cash Flow | 846.88 | -958.86 | 863.24 | -171.85 | 3,037 | 107.85 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | - | -0 | - | Upgrade
|
| Net Cash Flow | -236.98 | -133.2 | -246.58 | -1,416 | 2,985 | 1.37 | Upgrade
|
| Free Cash Flow | -1,095 | 769.4 | -1,283 | -923.43 | -52.3 | -21.1 | Upgrade
|
| Free Cash Flow Margin | -8.44% | 6.20% | -10.35% | -9.44% | -0.90% | -0.60% | Upgrade
|
| Free Cash Flow Per Share | -4.80 | 3.37 | -5.62 | -4.07 | -0.28 | -0.21 | Upgrade
|
| Cash Interest Paid | 289.99 | 289.99 | 329.3 | 58.73 | 39.22 | 41.31 | Upgrade
|
| Cash Income Tax Paid | 461.13 | 461.13 | 367.92 | 309.61 | 126.46 | 51.39 | Upgrade
|
| Levered Free Cash Flow | -1,405 | 469.5 | -1,324 | -1,497 | 759.74 | -37.41 | Upgrade
|
| Unlevered Free Cash Flow | -1,201 | 654.15 | -1,240 | -1,461 | 782.08 | -12.62 | Upgrade
|
| Change in Net Working Capital | 1,992 | -330.6 | 1,106 | 1,559 | -636.23 | 108.53 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.